We’re living the COVID comeback, but the immunocompromised among us may still need to wear mask. We need to show kindness, not indignation.

Mark Cuban's latest venture may shift people's perception on the drug supply chain. That's a welcome opportunity to rethink it.

The very latest official CBO report now states unequivocally: It's "unlikely" drug net prices have increased, and they declined in Medicare

The majority of "drug spending" isn't really on drugs. When it comes to overall spending on pharmaceuticals, only 37% go to manufacturers.

Per CMS: Drug prices are not skyrocketing on the list price level and they are in fact declining for yet another year on net prices.

What would happen if drug price 'negotiation' brought down pharma list prices across the board? Not much at all, at least not for...

New research by David Cuttler with McKinsey and Partners published in JAMA shows that there are $250B in healthcare savings annually....

From NYC to Texas, the feeling going into this Memorial Day weekend is that we're finally done with COVID. But is the virus done with us?

The US reimbursement landscape has been shifting rapidly over the last few years. We invited 31 MCO leaders to discuss the key trends.

Evaluating drug candidates for M&A is of the essential parts of R&D innovation. This article proposes an interdisciplinary approach.